ZVRA Form 4: CEO Settlement of 50,000 RSUs and Planned Sale
Rhea-AI Filing Summary
Neil F. McFarlane, President and CEO of Zevra Therapeutics, Inc. (ZVRA), reported equity transactions on 10/10/2025. He received 50,000 restricted stock units (RSUs) that vested and settled under the company plan, bringing his direct holding to 241,516 shares. On the same date he sold 19,500 shares at a price of $10.8158, leaving him with 222,016 shares. The RSUs were part of an inducement award where 25% vested and settled on 10/10/2024 and another 25% on 10/10/2025, with the remaining 50% vesting in equal annual installments thereafter subject to continued employment; full vesting also occurs on a change of control or certain termination events. The sale was made pursuant to a 10b5-1(c) plan adopted 03/21/2025.
Positive
- 50,000 RSUs vested and settled, increasing alignment of CEO with shareholder value
- Sale executed under a 10b5-1(c) plan adopted on 03/21/2025, indicating a pre-planned compliance mechanism
Negative
- 19,500 shares sold at $10.8158, reducing direct shareholdings to 222,016
Insights
CEO received vested RSUs and executed a planned sale under a 10b5-1 plan.
The transaction combined a routine vesting/settlement of 50,000 RSUs with a contemporaneous sale of 19,500 shares at $10.8158. The RSU vesting schedule is explicit: 25% vested on 10/10/2024, 25% on 10/10/2025, with the remainder vesting annually thereafter subject to employment.
Dependence and near-term items to watch include continued employment status for remaining vesting and any change-of-control triggers that would accelerate vesting. The 03/21/2025 10b5-1 plan provides procedural protection for the sale; monitor future Form 4s for additional planned sales or accelerated vesting events.
Transactions follow typical governance and disclosure practices for executive awards.
The filings show direct beneficial ownership and an attorney-in-fact signature, consistent with standard SEC reporting. The combination of a planned sale and RSU settlement is common when executives realize liquidity while retaining a significant ownership stake—here remaining at 222,016 shares after the sale.
Risks are administrative: verify the 10b5-1 adoption date and plan terms if assessing potential insider trading defense; significant corporate events that change employment status could materially affect share counts and should be checked against future disclosures.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 50,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 50,000 | $0.00 | $0.00 |
| Sale | Common Stock | 19,500 | $10.8158 | $211K |
Footnotes (3)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F2. Adoption date of referenced 10b5-1(c) plan is: 03-21-2025.
- F3. 25% of the RSUs vested and settled on each of October 10, 2024 and October 10, 2025. The remaining 50% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.
AI-generated analysis. How Rhea-AI works. Not financial advice.
